Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma

Recently, immune checkpoint therapy was shown to be very effective in the treatment of several cancers by reactivating the immune system. This was also shown for hard to treat cancers such as melanoma and lung cancer. At the forefront of immune checkpoint therapy are antibodies targeting cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and the programmed cell death-1 (PD-1). However, clinical success of immune checkpoint inhibitors greatly varies between different cancer types, ranging from objective responses in 65-87% of Hodgkin lymphoma (HL) patients to around 30% in other malignancies [reviewed by [1 –3]].

Source: Cancer Treatment Reviews - November 10, 2019 Category: Cancer & Oncology Authors: Johanna Veldman, Lydia Visser, Anke van den Berg, Arjan Diepstra Tags: Anti-Tumour Treatment Source Type: research